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Esophageal adenocarcinoma is the most common type of esophageal cancer in most
Western countries and is an important contributor to overall cancer mortality. Most cases
of esophageal adenocarcinoma are believed to arise from Barrett’s esophagus. Esophageal
adenocarcinoma occurs more frequently in white men over 50 years old, as well as in
people with frequent symptoms of gastroesophageal reﬂux, in smokers and in people
who are obese. Higher consumption of fruit and vegetables, use of non-steroidal anti-
inﬂammatory drugs, and infection with Helicobacter pylori have all been shown to reduce
the risk of esophageal adenocarcinoma. Here, we review the epidemiological evidence for
the major risk factors of esophageal adenocarcinoma and also discuss perspectives for
future research.
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INTRODUCTION
Worldwide, esophageal cancer is the eighth most common malig-
nancy and the sixth leading cause of cancer mortality. Recent
estimates suggest 482,000 new cases of esophageal cancer arise
worldwide each year, resulting in 407,000 deaths (Ferlay et al.,
2010). The lifetime risk of esophageal cancer in the United States
is about 1 in 125 men and about 1 in 400 women (American
Cancer Society, 2011). Two predominant histopathologic types
of esophageal cancer are recognized: squamous cell carcinoma
(ESCC) and adenocarcinoma (EAC). In Western countries, the
rate of increase in EAC incidence during the past four decades has
been among the highest for any cancer (Pohl and Welch, 2005).
Prognosis for patients with EAC is strongly related to stage at diag-
nosis, however most patients are diagnosed with late-stage disease
and less than 20% survive for 5 years (Stavrou et al., 2009).
The last two decades have seen increasing research atten-
tion given to the epidemiology of EAC. Numerous population-
based epidemiological studies have examined EAC risk fac-
tors; however the small size of these individual studies has
limited the precision of resulting risk estimates and reconcil-
ing inconsistent ﬁndings have proven difﬁcult. Valuable insights
have been gained from the output from the Barrett’s and
Esophageal Adenocarcinoma Consortium (BEACON), a collab-
orative project which has pooled the data from 12 of these
studies (http://bea.tlvcloud.org/), thereby conferring greater sta-
tistical precision. The analyses combine 10 case–control stud-
ies and 2 cohort studies from the United States, Canada,
the United Kingdom, Ireland, Australia, and Sweden, involving
more than 2,100 EAC patients and almost 14,000 population
Abbreviations: BE, Barrett’s esophagus; EAC, esophageal adenocarcinoma; ESCC,
esophageal squamous cell carcinoma; GER, gastroesophageal reﬂux; NSAIDs,
non-steroidal anti-inﬂammatory drugs.
controls (Cook et al., 2010). Much of the discussion and con-
clusions regarding risk factors in this review is based on these
pooled analyses; where appropriate other articles have also been
cited.
Most cases of EAC are believed to arise from underlying Bar-
rett’s esophagus (BE), a premalignant condition in which the
normal stratiﬁed squamous epithelium of the distal esophagus
is replaced by specialized columnar epithelium (Falk, 2002). Here,
we will provide an overview of the descriptive epidemiology of
EAC and BE, and provide a summary of the risk factors for these
conditions. This review is restricted to the effects of host charac-
teristics and environmental exposures, and does not address risks
associated with constitutional genotypes, since several large-scale
genome-wide association studies are being conducted currently
and will publish their ﬁndings shortly.
DESCRIPTIVE EPIDEMIOLOGY
Incidence rates for EAChave increased sharply during the past four
decades in developed countries, with a reported seven-fold (0.36–
2.56 per 100,000) increase in the United States between 1973 and
2006 (Pohl et al., 2010). Increases in incidence of similar magni-
tude have been reported among populations residing in Australia,
Denmark, Finland, Norway, Sweden, Switzerland, and the United
Kingdom (Botterweck et al., 2000; Vizcaino et al., 2002; Bosetti
et al., 2008; Cook et al., 2009; Stavrou et al., 2009). As a result of
these increases,EACbecame themost common formof esophageal
cancer in the United States and most other Western countries in
the late 1990s (Curado et al., 2007; Holmes and Vaughan, 2007).
In all populations, the greatest increase in incidence has been
observed among older white men. However, incidence rates have
also increased signiﬁcantly among other ethnic groups, in women,
and in people less than 65 years old (Holmes and Vaughan, 2007;
Brown et al., 2008).
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Figure 1 presents the age-adjusted annual incidence rates for
EAC from a broad geographical range of cancer registries and
highlights the considerable international variation in EAC inci-
dence (Curado et al., 2007). Notably, rates also vary among dif-
ferent ethnic groups within a particular country. For example,
in the United States, compared with non-Hispanic whites, the
incidence of EAC is signiﬁcantly lower among Hispanic whites,
Blacks, Asians, and Paciﬁc Islanders (Cook et al., 2009). Migra-
tion studies have shown that EAC rates tend to approach those
of the country of adoption rather than the country of ori-
gin, suggesting variation within countries is unlikely to be fully
explained by racial or genetic differences. Another remarkable fea-
ture is the sex ratio, with most populations reporting more than
ﬁve-fold higher incidence in men than women (Curado et al.,
2007). EAC is rare among young persons (80% of EAC cases
are aged 55–70 years) and incidence increases with age (mean
age at diagnosis is 60 years; Yang and Davis, 1988; Lagergren,
2005).
BARRETT’S ESOPHAGUS
As the precursor to EAC, BE is frequently asymptomatic, preva-
lence is largely unknown and it is thought that a large percentage
of the general population may have undiagnosed BE (Cameron
et al., 1990). Population prevalence estimates for BE have been
gained from autopsy and endoscopy series. In an autopsy study in
Olmsted County,Minnesota, the prevalence of BE was reported to
be as low as 0.4% (Cameron et al., 1990). Data from endoscopic
surveys completed in Sweden (Ronkainen et al., 2005) and Italy
(Zagari et al., 2008) suggest that 1.3–1.6% of the population have
BE. However, according to data from the United States, the upper
bound of population prevalence of BE may be as high as 6% (Rex
et al., 2003; Hayeck et al., 2010).
Analyses of temporal trends for BE patients have failed to deter-
mine whether BE incidence has truly increased. While several
studies have investigated the recent increases in diagnosis of BE,
it remains unclear whether the observed increase in incidence of
BE is real or whether increased awareness and widespread use of
endoscopy have resulted in more diagnoses (Prach et al., 1997;
van Soest et al., 2005; Kendall and Whiteman, 2006; Musana et al.,
2008).
Overall, the associations between sociodemographic charac-
teristics and the risk of BE are similar to those for EAC. Epi-
demiological data suggest a 2:1 male predominance for BE (Cook
et al., 2005). There is consensus in the literature that BE develops
more frequently in older people, with most BE patients diagnosed
between 50 and 60 years of age (Corley et al., 2009). Finally, com-
parable with EAC,BE is more commonly diagnosed in whites than
in other ethnic groups (including Blacks, Asians, and Hispanics;
Ford et al., 2005; Corley et al., 2009).
CANCER RISK IN BARRETT’S ESOPHAGUS
Adenocarcinoma is thought to arise through a progressive
sequence, whereby the abnormal columnar epithelium that char-
acterizes BE progresses to low-grade dysplasia, then to high-grade
dysplasia and ﬁnally to carcinoma (Hamilton and Smith, 1987;
Hameeteman et al., 1989; Miros et al., 1991). The absolute risk
of EAC in patients with BE is unclear however, with earlier
studies reporting higher risks than more recent studies (Sha-
heen et al., 2000; Sikkema et al., 2010). Although previously
assumed to be between 5 and 10 per 1,000 person-years, a recent
large, population-based study in Denmark reported a much lower
absolute risk of progression to EAC of 1.2 per 1,000 person-years
(Hvid-Jensen et al., 2011). The risk is substantially higher however
in BE patients with dysplasia (5.1 vs. 1.0 cases per 1,000 person-
years among patients with low-grade dysplasia compared with
patients without dysplasia; Hvid-Jensen et al., 2011). It is unclear
why adenocarcinoma develops in only a small subset of those with
BE, as the pathways leading to EAC remain ill-deﬁned. The pro-
gressively lower estimates of annual risk of EAC in BE patients
raise questions about the feasibility of endoscopic surveillance in
patients who have BE. Future research will need to develop better
tools for stratifying patients based on risk of progression. Numer-
ous approaches are being investigated currently, including clinical
decision algorithms, serological markers, and tissue-based prog-
nostic markers (Rabinovitch et al., 2001; Risques et al., 2007; Sato
et al., 2008; Merlo et al., 2010).
FIGURE 1 | Age-adjusted annual incidence of esophageal adenocarcinoma (per 100,000; Data source: Curado et al., 2007).
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Table 1 | Summary of risk factors for esophageal adenocarcinoma.
Risk factors Magnitude of risk
ESTABLISHED RISK FACTORS
Geographical region (Western countries) ++
Male gender ++
Caucasian race ++
Barrett’s esophagus ++
Gastroesophageal reﬂux ++
Obesity ++
Tobacco smoking +
Dietary fats +
ESTABLISHED PROTECTIVE FACTORS
Fruit and vegetables consumption − −
Dietary antioxidants − −
Non-steroidal anti-inﬂammatory drugs − −
H. pylori infection − −
NOTASSOCIATED
Total alcohol consumption 0
Carbonated soft drinks 0
EQUIVOCAL FACTORS
Hot beverages (tea and coffee) ?
0, no association; +, low to moderate increase in risk; ++, moderate to high
increase in risk; − −, moderate to high decrease in risk; ?, ambiguous studies.
ENVIRONMENTAL EXPOSURES
Esophageal adenocarcinoma is a multifactorial disease. The tem-
poral trends in epidemiology and the effect of migration on
incidence suggest that environmental factors play an important
role in the etiology of EAC (Table 1).
GASTROESOPHAGEAL REFLUX
Gastroesophageal reﬂux (GER), a condition that occurs when the
lower esophageal sphincter allows stomach acid to ﬂow back into
the esophagus, is becoming increasingly common inWestern pop-
ulations (Ness-Jensen et al., 2011). Long-standing GER is a major
risk factor predisposing to the development of BE and EAC, and
is thought to play a role in progression from BE to cancer. A
recent meta analysis of ﬁve large population-based case–control
studies reported that the relative risks of EAC associated with at
least weekly GER symptoms and daily symptoms are around ﬁve
and seven, respectively (Rubenstein and Taylor, 2010). There is
also general agreement that chronic GER is the main cause of BE
(Falk, 2002), with frequent GER symptoms associated with 10-
fold greater risk of developing BE (Anderson et al., 2007; Kubo
et al., 2009a; Smith et al., 2009). The evidence regarding the effect
of longer duration of GER symptoms and risks of EAC and BE
is inconclusive (Anderson et al., 2007; Rubenstein and Taylor,
2010).
Due to the role of GER in the development of EAC, var-
ious acid suppression therapies have been used to reduce
esophageal acid exposure in BE patients. Findings to date sug-
gest that acid-suppressant medications may reduce the risk
of progression from BE to cancer (El-Serag et al., 2004;
Hillman et al., 2004, 2008; Cooper et al., 2006; Nguyen
et al., 2009), but deﬁnite evidence from clinical trials is
lacking. Furthermore, it is not known whether these med-
ications may prevent the development of BE in the ﬁrst
place.
The biological mechanisms whereby GER causes BE and
inﬂuences the development of EAC is still unclear. Two main
hypotheses have arisen in response to experimental and epidemi-
ological data. The prevailing hypothesis is that chronic reﬂux
of acid or bile injures the esophageal epithelium, inducing a
cascade of cytokine responses that result in inﬂammation and
cell proliferation, thereby initiating the metaplasia–dysplasia–
neoplasia sequence (Yoshida, 2007). The second hypothesis is
that GER may cause the production of nitrous oxide from
ingested nitrites, leading to elevated levels of DNA damage
and enhanced risk of disease through increasing the likelihood
of genetic change (Clemons et al., 2007). These hypotheses
are not mutually exclusive however, and other mechanisms are
also possible. Research to ﬁll these gaps in our knowledge is
ongoing.
OBESITY
Obesity is one of the strongest risk factors for EAC, but less so
for BE. Population-based studies have consistently reported that
a body mass index (BMI) greater than 30.0 kg/m2 is associated
with two- to three-fold increased risk of EAC (Corley et al., 2008b;
Whiteman et al., 2008). A recent meta analysis found some evi-
dence of an association between BMI and BE (Kamat et al., 2009),
however more recent attention has focused on whether body fat
distribution (in particular, more centralized visceral fat) may be a
better marker of risk than BMI. Increased central adiposity (waist
circumference, waist-to-thigh ratio, and waist-to-hip ratio) has
been reported to strongly and signiﬁcantly increase the risk of BE,
independent of BMI (Corley et al., 2007; Edelstein et al., 2007).
Since fat is more likely to be distributed around the abdomen in
men, and since visceral fat produces high levels of inﬂammation-
related cytokines (such as leptin; Williams et al., 2000; Considine,
2001), this may explain some of the gender-related difference in
the incidence of BE. However, while leptin is known to be up-
regulated in obesity and in vitro studies have shown that leptin
promotes proliferation in EAC cells, the evidence regarding the
effect of leptin on BE risk is inconclusive. Although high leptin
levels have been reported to increase the risk of BE in two stud-
ies, one study observed a stronger effect in men (Kendall et al.,
2008), and the only other study observed a stronger effect in
women (Thompson et al., 2010). Resolution of the relationship
between leptin and risk of BE requires more data from larger
studies.
Despite the strong associations between BMI and EAC risk,
there is some doubt as to whether the rise in obesity explains all
of the increase in EAC incidence and whether BMI increases risk
independently of obesity-related inﬂammation. A recent study has
suggested that the increase in EAC incidence preceded the rise in
obesity prevalence by a decade (Abrams et al., 2011), and data
from a simulation model indicated that increasing obesity may
only explain a small percentage (6.5%) of the rise in EAC inci-
dence (Kong et al., 2011). More work is needed to help disassociate
the role of obesity from chronic inﬂammation in EAC risk and to
understand the drivers of the shift in EAC incidence.
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SMOKING
Studies have consistently found a strong association between
tobacco smoking and EAC and, to a lesser extent, BE. Pooled
analyses estimate an approximate two-fold increased risk of EAC
associated with ever smoking, and a strong dose–response asso-
ciation with cumulative exposure (Cook et al., 2010). For BE,
the association is unclear, with some studies (Johansson et al.,
2007; Smith et al., 2009), but not all (Anderson et al., 2007;
Kubo et al., 2009a), reporting an approximately two-fold increased
risk among ever smokers but no consistent trend of increas-
ing risk with increasing quantity of cigarettes consumed. Recent
research suggests that tobacco smoking is also strongly asso-
ciated with progression from BE to cancer, with a two-fold
increased risk associated with ever smoking (Coleman et al.,
2012). At a mechanistic level, relatively little is understood about
how smoking might cause metaplasia and neoplasia of the distal
esophagus.
DIET
Dietary factors may partially explain aspects of risk variation by
sex, ethnicity and nationality, and may also account for some of
the changes in EAC incidence observed among migrants. While
many aspects of the role of diet on EAC and BE etiology remain
unclear, observational studies have reported that high levels of
consumption of saturated fat and processed meat, low fruit and
vegetable consumption, low dietary antioxidant intake, and low
intakes of certain minerals are all associated with increased risks
of both EAC and BE (Mayne et al., 2001; Anderson et al., 2007;
Kubo and Corley, 2007; Wu et al., 2007; Kubo et al., 2008a,b, 2009;
Mulholland et al., 2009; Thompson et al., 2009; Murphy et al.,
2010). The effects of meat and ﬁsh consumption are unclear. Evi-
dence to date suggests that neither hot beverages nor carbonated
soft drinks are consistently related to EAC risk (Lagergren et al.,
2006; Mayne et al., 2006; Ibiebele et al., 2008, 2010; Islami et al.,
2009; Ren et al., 2010). There is also no evidence that alcohol con-
sumption increases the risk of EAC or BE; indeed, recent studies
have suggested a possible inverse association with wine consump-
tion (Anderson et al., 2009; Kubo et al., 2009b; Freedman et al.,
2011; Thrift et al., 2011c).
MEDICATION USE
A prominent hypothesis posits that medications inducing relax-
ation of the lower esophageal sphincter (including calcium chan-
nel blockers, benzodiazepines, and asthma medications, among
others) may promote GER, thereby indirectly increasing the
risks of BE and EAC. Epidemiological studies have examined
their association with EAC, with inconsistent ﬁndings (Chow
et al., 1995; Vaughan et al., 1998; Farrow et al., 2000; Lager-
gren et al., 2000; Ranka et al., 2006; Fortuny et al., 2007). Few
studies have investigated associations between use of these med-
ications and BE risk (Corley et al., 2006; Ladanchuk et al.,
2010). While results suggest that regular users of asthma med-
ications may have an increased risk of EAC, residual confound-
ing may explain these ﬁndings since users of asthma medica-
tions report higher frequency of GER symptoms, and reﬂux is
strongly associated with EAC, BE, and reﬂux-associated asthma
symptoms.
NON-STEROIDAL ANTI-INFLAMMATORY DRUGS
There is consistent evidence from observational studies that fre-
quent users of non-steroidal anti-inﬂammatory drugs (NSAIDs)
have reduced risks of EAC (Corley et al., 2003; Liao et al., 2012),
and that NSAID use among BE patients may also reduce their
risk of progression to cancer by up to 70% (Vaughan et al., 2005).
However, to date, ﬁndings have been inconsistent for BE, with
one study reporting a halving of risk of BE among NSAID users
(Anderson et al., 2006), while the only other study reported no
association (Thrift et al., 2011b). In this respect, the discordant
ﬁndings for EAC and BE may be analogous to those observed for
colon cancer and polyps, whereby aspirin and other NSAID use
may stop progression from pre-cancer to cancer, but not the ini-
tial development of pre-cancer. Deﬁnitive evidence to resolve this
issue awaits the ﬁndings from randomized trials (Jankowski and
Moayyedi, 2004).
HELICOBACTER PYLORI INFECTION
Helicobacter pylori is a Gram-negative bacterium that persis-
tently colonizes the human stomach (Suerbaum and Michetti,
2002; Blaser and Atherton, 2004; Atherton and Blaser, 2009),
and is a major cause of gastric cancer (Huang et al., 1998;
Atherton and Blaser, 2009). In contrast, epidemiological stud-
ies have reported that persons infected with H. pylori have
half the risks of EAC and BE than those uninfected (Rokkas
et al., 2007; Anderson et al., 2008; Corley et al., 2008a; Islami
and Kamangar, 2008; Whiteman et al., 2010; Thrift et al., 2011a).
It is postulated that the decline in infection rates for H.
pylori in Western populations may have contributed to the
changing epidemiology of EAC. A possible explanation for the
inverse association is reduced acid secretion in those infected,
with ongoing research focusing on the mechanisms through
which H. pylori mediates its effects on esophageal epithe-
lium.
CONCLUSION
Since the 1970s, the incidence of EAChas increased sharply inmost
Western countries. Explanations commonly offered to explain this
change in epidemiology of EAC include the rising prevalences of
central obesity and reﬂux among white men, although quantify-
ing the overall contribution of these factors remains the subject
of investigation. Given the rising prevalence of obesity world-
wide, especially in developing countries, and the links between
obesity, inﬂammation, and cancer, it is clear that a better under-
standing of these relationships is required to yield more targeted
strategies for cancer prevention. It is anticipated that research
currently being conducted will provide a better understanding
of the interplay between inherited susceptibility and environ-
mental factors. In the future, it is possible that such knowledge
will be applied to develop tools which will enable patients and
clinicians to quantify an individual’s absolute risk of develop-
ing esophageal cancer and thereby make appropriate decisions to
improve outcomes.
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